首頁 > 市場調查報告書 > 醫療設備

體外診斷感染疾病

市場調查報告書

商品編碼

2126349

流感診斷市場：策略性洞察與預測（2026-2035）

Influenza Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月04日 | 出版商:

Knowledge Sourcing Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計流感診斷市場規模將從 2026 年的 12.3 億美元成長到 2035 年的 20.2 億美元，複合年成長率為 5.7%。

流感診斷市場正經歷重大變革，其驅動力在於向分子檢測和呼吸系統疾病綜合管理模式轉移。這一市場演變的特點是，人們日益認知到準確且快速的診斷檢測對於確定抗病毒治療方案、控制感染和進行公共衛生監測至關重要。分子診斷、多重呼吸道病原體檢測和即時檢測技術的整合，使得流感檢測速度更快、靈敏度更高、覆蓋範圍更廣。醫療系統正在採用分子檢測技術，因為臨床決策，特別是對於住院患者和高風險患者，依賴快速靈敏的診斷結果。多參數呼吸道病原體檢測的擴展正在提升流感診斷水平，因為它能夠從單一檢體同時檢測流感病毒、呼吸道合胞病毒（RSV）和新冠病毒（SARS-CoV-2），從而提高鑑別診斷的準確性。季節性流感監測對於疫情防範和疫苗株的選擇仍然至關重要，政府監測計畫也不斷擴大其檢測能力。市場正在大力投資即時分子診斷平台、自動化檢測系統和數位連接解決方案，流感診斷被納入綜合呼吸系統疾病檢測生態系統。

市場促進因素

分子診斷技術的日益普及是流感診斷市場的主要驅動力。與傳統的抗原檢測相比，分子診斷具有更高的分析靈敏度和特異性，使其成為臨床上確診流感感染的首選方法。由於假陰性結果可能導致治療啟動和感染控制的延誤，醫療機構正擴大用RT-PCR和其他核酸擴增技術取代傳統的快速抗原檢測。診斷設備製造商正在擴展自動化「樣本到結果」系統，以減少對操作人員的依賴並縮短檢體週轉時間。這種技術變革正在增強醫院和關鍵檢查室對先進流感診斷平台的長期需求，從而推動流感診斷應用的持續成長。呼吸道疾病監測計畫的擴展透過提高檢測能力進一步加速了市場成長。國家監測計畫監測流感病毒的爆發情況，有助於識別季節性爆發、發現新出現的病毒株並確定疫苗配方。公共衛生部門正在不斷加強其檢測和監測網路，因為準確的流行病學資訊有助於及時採取乾預策略。診斷實驗室正在提升檢測能力，以滿足監測需求，並透過標準化的分子調查方法提高報告品質。不斷擴展的監測基礎設施正在推動流感診斷劑和檢測設備的永續供應。對多參數呼吸道檢測日益成長的需求正在推動綜合診斷試劑盒的普及。呼吸道感染疾病的症狀往往重疊，如果沒有實驗室確診，臨床診斷將會十分困難。醫療專業人員越來越傾向於使用多重診斷試劑盒，因為它們可以同時識別流感病毒和其他呼吸道病原體，從而降低診斷的不不確定性。製造商正在將流感檢測項目整合到綜合呼吸道檢測試劑盒中，從而提高檢查室效率並支持循證治療決策。這種診斷整合正在提升流感檢測在呼吸道疾病管理的策略價值。加強對季節性和大流行性呼吸道疾病威脅的防範，正在推動對診斷基礎設施的長期投資。由於流感病毒仍構成季節性疾病負擔和潛在的大流行威脅，醫療衛生系統正在優先考慮防範工作。世界各國政府正持續投資於檢測基礎設施、診斷儲備和緊急應變能力，以加強其在疫情爆發期間的檢測能力。

市場限制因素

快速抗原檢測臨床表現的差異性持續限制了其在高風險患者群體中的應用。這是因為低靈敏度可能需要進行分子檢測以確認結果。抗原檢測的低靈敏度會為臨床決策帶來診斷上的不確定性。分子診斷平台需要專門的檢查室基礎設施、訓練有素的人員以及高昂的營運成本，這限制了其在資源有限的醫療機構中的應用。分子診斷平台所需的大量投資對小規模醫療機構而言也是一大障礙。流感發病率的季節性波動導致檢測需求不穩定，使醫療機構的長期檢查室容量規劃和庫存管理更具挑戰性。季節性疫情的不可預測性也使資源分配更加複雜。不同司法管轄區的監管複雜性也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

依產品
- 裝置
- 試劑和試劑盒
- 耗材和配件
按測試類型
- 快速流感診斷測試（RIDT）
- 分子診斷（RT-PCR 和 NAAT）
- 免疫學檢測方法
- 病毒培養試驗
- 其他
透過技術
- 聚合酵素鏈鎖反應（PCR）
- 恒溫核酸增幅法
- 免疫測量
- 次世代定序
依樣本類型
- 鼻咽拭子
- 口腔和咽拭子
- 鼻拭子
- 其他
最終用戶
- 醫院和診所
- 診斷檢查室
- 門診部
- 其他
透過分銷管道
- 離線
  - 直銷
  - 零售藥房
- 線上

第10章：全球流感診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：全球流感診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
墨西哥
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

Roche Holding AG
Abbott Laboratories
Becton, Dickinson and Company
bioMerieux SA
QuidelOrtho Corporation
Danaher Corporation
Sekisui Chemical Co., Ltd.
Thermo Fisher Scientific Inc.
Princeton BioMeditech Corporation
Meridian Bioscience, Inc.

第14章：全球流感診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009060

The Influenza Diagnostics Market is expected to grow at a CAGR of 5.7% from a market value of USD 1.23 billion in 2026 to USD 2.02 billion in 2035.

The influenza diagnostics market is undergoing significant transformation driven by the paradigm shift toward molecular testing and integrated respiratory disease management. The market's evolution is characterized by the growing recognition that accurate and rapid laboratory confirmation is essential for antiviral treatment decisions, infection control, and public health surveillance. The convergence of molecular diagnostics, multiplex respiratory panels, and point-of-care technologies is enabling faster, more sensitive, and increasingly comprehensive influenza detection. Healthcare systems are adopting molecular testing technologies because clinical decision-making depends on rapid and highly sensitive diagnostic results, particularly for hospitalized and high-risk patients. The expansion of multiplex respiratory testing is strengthening influenza diagnostics because simultaneous detection of influenza, RSV, and SARS-CoV-2 improves differential diagnosis from a single specimen. Government surveillance programs continue expanding laboratory testing capacity because seasonal influenza monitoring remains essential for outbreak preparedness and vaccine strain selection. The market is witnessing significant investment in point-of-care molecular platforms, automated laboratory systems, and digital connectivity solutions, positioning influenza diagnostics within an integrated respiratory disease testing ecosystem.

Market Drivers

The increasing adoption of molecular diagnostic technologies represents the primary driver for the influenza diagnostics market. Molecular diagnostics provide superior analytical sensitivity and specificity compared with conventional antigen-based assays, making them the preferred choice for clinical confirmation of influenza infection. Healthcare providers are increasingly replacing traditional rapid antigen testing with RT-PCR and other nucleic acid amplification technologies because false-negative results may delay treatment initiation and infection control measures. Diagnostic manufacturers are expanding automated sample-to-answer systems that reduce operator dependency and turnaround time. This technological transition strengthens long-term demand for advanced influenza diagnostic platforms across hospitals and centralized laboratories, resulting in sustained growth in influenza diagnostic utilization. The expansion of respiratory disease surveillance programs is further accelerating market growth through increased testing capacity. National surveillance programs monitor influenza virus circulation to identify seasonal outbreaks, detect emerging strains, and inform vaccine composition. Public health authorities are continuously strengthening laboratory surveillance networks because accurate epidemiological information supports timely intervention strategies. Diagnostic laboratories are increasing testing capacity to accommodate surveillance requirements while improving reporting quality through standardized molecular methodologies. This expanding surveillance infrastructure reinforces sustained procurement of influenza diagnostic reagents and laboratory instruments. The growing demand for multiplex respiratory testing is driving adoption of comprehensive diagnostic panels. Respiratory infections frequently present with overlapping symptoms that complicate clinical diagnosis without laboratory confirmation. Healthcare providers are increasingly requesting multiplex diagnostic panels because simultaneous identification of influenza viruses and other respiratory pathogens reduces diagnostic uncertainty. Manufacturers are integrating influenza targets into comprehensive respiratory panels that improve laboratory efficiency while supporting evidence-based treatment decisions. This diagnostic consolidation increases the strategic value of influenza testing within respiratory disease management. Rising preparedness for seasonal and pandemic respiratory threats is sustaining long-term investment in diagnostic infrastructure. Healthcare systems prioritize preparedness because influenza viruses remain capable of generating significant seasonal disease burden and potential pandemic threats. Governments are continuing investments in laboratory infrastructure, diagnostic stockpiles, and emergency response capacity that improve testing readiness during outbreaks.

Market Restraints

Clinical performance variability among rapid antigen tests continues to limit adoption in high-risk patient populations because reduced sensitivity may require confirmatory molecular testing. The lower sensitivity of antigen tests creates diagnostic uncertainty for clinical decision-making. Molecular diagnostic platforms require specialized laboratory infrastructure, trained personnel, and higher operational costs, restricting adoption across resource-limited healthcare settings. The significant investment required for molecular platforms creates barriers for smaller facilities. Seasonal fluctuations in influenza incidence create variable testing demand, making long-term laboratory capacity planning and inventory management more challenging for healthcare providers. The unpredictability of seasonal outbreaks complicates resource allocation. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated respiratory diagnostic platforms and automation. Molecular diagnostics represent the fastest-evolving segment because healthcare providers require highly sensitive and specific influenza detection to support early therapeutic intervention and infection control. Hospitals are increasingly adopting RT-PCR and other nucleic acid amplification technologies as frontline diagnostic tools since they reduce false-negative results associated with conventional antigen testing. Higher testing accuracy supports appropriate antiviral prescribing while improving surveillance data used for monitoring seasonal influenza circulation. Manufacturers are responding by developing automated sample-to-answer systems, multiplex respiratory panels, and scalable laboratory platforms that shorten turnaround time without compromising analytical performance. PCR remains the dominant molecular technology for influenza detection. Isothermal nucleic acid amplification is expanding for point-of-care and decentralized testing. Immunoassays continue supporting rapid antigen testing in outpatient and low-resource settings. The segment analysis reveals that nasopharyngeal swabs remain the preferred specimen type because they consistently provide high viral concentrations during the early stages of influenza infection, supporting accurate laboratory diagnosis. Clinical laboratories continue relying on this collection method since it aligns with validated protocols used across molecular and antigen-based diagnostic platforms. Hospitals and clinics account for the greatest diagnostic demand because influenza diagnosis directly influences treatment initiation, patient isolation, emergency department workflow, and hospital infection prevention programs. Healthcare institutions are expanding molecular testing capacity as respiratory disease management increasingly depends on rapid laboratory confirmation. Diagnostic laboratories are increasing testing capacity to accommodate surveillance requirements. The integration of digital connectivity is becoming increasingly important because diagnostic manufacturers are incorporating connectivity features that enable automated result transmission, quality monitoring, and integration with laboratory information systems.

Competitive and Strategic Outlook

The competitive landscape features established molecular diagnostics companies alongside specialized rapid test and point-of-care providers. Roche differentiates itself through its cobas molecular diagnostic platform, which provides highly automated, high-throughput influenza and multiplex respiratory testing for clinical laboratories, continuing to expand integrated molecular solutions that support respiratory disease surveillance and hospital laboratory automation. Abbott maintains a strong position through its ID NOW rapid molecular platform and Alinity diagnostic systems, enabling decentralized influenza testing with rapid turnaround times, with its broad global distribution network and point-of-care expertise strengthening adoption across hospitals, clinics, and urgent care settings. BD leverages its expertise in specimen collection systems and molecular diagnostics to support accurate influenza testing across clinical laboratories, focusing on improving diagnostic workflow efficiency through integrated sample management and automated laboratory solutions. bioMerieux is strategically positioned through its BIOFIRE Respiratory Panel, which enables simultaneous detection of influenza and multiple respiratory pathogens from a single patient sample, continuing to invest in syndromic testing technologies that enhance clinical decision-making and laboratory productivity. QuidelOrtho combines rapid antigen testing and molecular diagnostics to address diverse healthcare settings ranging from physician offices to centralized laboratories, expanding its respiratory diagnostics portfolio by strengthening multiplex testing capabilities and point-of-care solutions. Danaher, through subsidiaries such as Cepheid and Beckman Coulter Diagnostics, offers comprehensive molecular influenza testing solutions with automated sample-to-answer workflows, continuing to strengthen its respiratory diagnostics portfolio by integrating scalable molecular platforms with advanced laboratory informatics. Companies are pursuing product portfolio expansion through innovation in multiplex respiratory panels, point-of-care molecular tests, and digital connectivity solutions. Recent key developments include New England Biolabs launching the NEBNext Flu A Integrated Indexing Primer Module, a curated set of 48 universal Influenza A RT-PCR primer pairs for use upstream of Oxford Nanopore Technologies sequencing. Microbix Biosystems launched QAPs quality assessment products and QUANTDx reference materials to support antigen or molecular tests for H3N2 strains of influenza A. QuidelOrtho announced availability of the QUICKVUE Influenza + SARS Test for professional use, a rapid immunoassay providing simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2 antigens. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The influenza diagnostics market is positioned for sustained growth driven by the convergence of molecular testing adoption, multiplex respiratory diagnostics, and expanding surveillance infrastructure. The transition from conventional antigen testing toward molecular and multiplex respiratory platforms represents a fundamental evolution in respiratory disease management. While challenges related to cost, infrastructure requirements, and seasonal variability persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with influenza diagnostics evolving from seasonal testing toward a year-round respiratory disease management model, supporting improved clinical decision-making, antimicrobial stewardship, and pandemic preparedness across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Influenza Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Influenza Disease Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Influenza Epidemiology & Disease Burden Analysis
3.8 Diagnosed Patient Population Analysis
3.9 Influenza Testing Volume Analysis
3.10 Diagnostic Testing Pathway & Clinical Workflow
3.11 Diagnostic Guidelines & Testing Recommendations

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Diagnostic Technologies
6.2 Product Innovation Analysis
6.3 Clinical Trial Analysis
6.4 Pipeline Diagnostics Analysis
6.5 AI Integration in Influenza Diagnostics
6.6 Digital Health Integration

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Influenza Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Testing Methodology
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Point-of-Care vs Laboratory-Based Testing

9. Global Influenza Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product
- 9.1.1 Instruments
- 9.1.2 Reagents & Kits
- 9.1.3 Consumables & Accessories
9.2 By Test Type
- 9.2.1 Rapid Influenza Diagnostic Tests (RIDTs)
- 9.2.2 Molecular Diagnostics (RT-PCR & NAAT)
- 9.2.3 Immunological Assays
- 9.2.4 Viral Culture Tests
- 9.2.5 Others
9.3 By Technology
- 9.3.1 Polymerase Chain Reaction (PCR)
- 9.3.2 Isothermal Nucleic Acid Amplification
- 9.3.3 Immunoassays
- 9.3.4 Next-Generation Sequencing
9.4 By Sample Type
- 9.4.1 Nasopharyngeal Swab
- 9.4.2 Oropharyngeal Swab
- 9.4.3 Nasal Swab
- 9.4.4 Others
9.5 By End User
- 9.5.1 Hospitals & Clinics
- 9.5.2 Diagnostic Laboratories
- 9.5.3 Ambulatory Care Centers
- 9.5.4 Others
9.6 By Distribution Channel
- 9.6.1 Offline
  - 9.6.1.1 Direct Sales
  - 9.6.1.2 Retail Pharmacy
- 9.6.2 Online

10. Global Influenza Diagnostics Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Influenza Diagnostics Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 Roche Holding AG
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Abbott Laboratories
13.3 Becton, Dickinson and Company
13.4 bioMerieux SA
13.5 QuidelOrtho Corporation
13.6 Danaher Corporation
13.7 Sekisui Chemical Co., Ltd.
13.8 Thermo Fisher Scientific Inc.
13.9 Princeton BioMeditech Corporation
13.10 Meridian Bioscience, Inc.